MOONLAKE IMMUNOTHERAPEUTICS Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for the quarter ending 2025-03-31 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for the quarter ending 2024-09-30 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for fiscal 2024 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS stock issued during period, value, conversion of convertible securities for fiscal 2023 was $0.00.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-11-07 | |
| 2022-06-30 | $1.58K 10-Q · filed 2023-11-14 | |
| 2021-06-30 | $27.66M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |